Latest Insights - page 27 | BiopharmaTrend

AI Drug Discovery Firm XtalPi Secures $100M Upfront in a Deal with DoveTree, Eyes $10B+ in Milestones

XtalPi has signed a letter of intent with DoveTree LLC, a company founded by Harvard University professor Gregory Verdine, to develop small molecule and antibody drug candidates using XtalPi’s AI- …

Continue ›››

Arc Institute Releases its First Virtual Cell Model

Arc Institute has launched its first virtual cell model, State, designed to predict gene expression changes in response to chemical, genetic, or cytokine perturbations across diverse cell types. The model is …

Continue ›››

12 Startups Applying AI to Gene Editing: From Custom CRISPR to Zinc-Finger Revivals

In May 2025, clinicians at Children’s Hospital of Philadelphia and Penn Medicine successfully performed a personalized CRISPR-based therapy on a newborn diagnosed with CPS1 deficiency—a rare genetic disorder impairing ammonia clearance in the liver. Built …

Continue ›››

NVIDIA Releases Agentic AI Blueprint for Literature Review and Target Discovery

NVIDIA has released a new AI-driven workflow, the Biomedical AI-Q Research Agent Developer Blueprint, designed to accelerate the early phases of drug discovery by automating literature review and hypothesis generation. …

Continue ›››

Nabla Raises $70M Series C to Expand Agentic AI Platform for Clinical Workflows

Nabla, developer of a widely adopted AI assistant used by over 130 healthcare organizations, has raised a $70 million Series C round led by HV Capital, bringing its total funding …

Continue ›››

Axiom Bio Releases Human Liver Toxicity Dataset with 130,000 Compounds to Advance AI-based Toxicity Prediction

San Francisco-based startup Axiom Bio, previously backed by $15 million in seed funding from investors including Amplify Partners, Dimension Capital, and Zetta Ventures, has released a publicly accessible data exploration …

Continue ›››

Xaira Publishes Largest Public Perturb-seq Atlas to Advance Virtual Cell Modeling

Xaira Therapeutics has announced the release of "X-Atlas/Orion", a large genome-wide Perturb-seq dataset, reportedly the largest publicly available resource of its kind. The dataset includes information from 8 million individual cells, …

Continue ›››

Agenus and Noetik Partner to Develop AI-Based Biomarkers Using Virtual Cell Models

Agenus has partnered with San Francisco-based Noetik to develop AI-enabled predictive biomarkers for its lead immunotherapy regimen, botensilimab (BOT) and balstilimab (BAL). The collaboration aims to improve clinical response prediction …

Continue ›››

Isomorphic Labs Appoints Ben Wolf as Chief Medical Officer, Expands to U.S. Hub in Cambridge

Isomorphic Labs has appointed Dr. Ben B. Wolf as Chief Medical Officer and opened a new U.S. office in Cambridge, Massachusetts, marking a strategic expansion following its $600M raise as …

Continue ›››

Ryght AI Raises $3M to Automate Clinical Trial Site Activation with Agentic AI

Laguna Beach–based Ryght AI, co-founded by Simon Arkell and Alex Dickinson in mid-2023, develops agentic and generative AI tools to accelerate clinical trial operations. The company claims to have built digital twins …

Continue ›››

AstraZeneca Signs $5.3B AI Drug Discovery Deal with CSPC for Chronic Disease Programs

AstraZeneca has signed a licensing and co-discovery agreement with CSPC Pharmaceutical Group worth up to $5.3 billion, including $110 million in upfront cash. The partnership will focus on discovering new …

Continue ›››

Insilico Medicine Completes Oversubscribed Series E, Bringing Total Funding to $123 Million

Insilico Medicine has finalized its Series E round at $123 million, up from the $110 million first announced in March 2025. The round was led by Value Partners Group, with …

Continue ›››